Pembrolizumab + Idelalisib for Lung Cancer Study

Non Small Cell Lung Cancer Clinical Trial

— PIL  

Official title:

A Phase Ib /II Trial of Pembrolizumab and Idelalisib in Patients With Non-small Cell Lung Cancer (NSCLC) Who Have Failed Immune Checkpoint Inhibitor

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03257722
• Other study ID #: GCC-16053
• Status: Terminated
• Phase: Phase 1/Phase 2
• Start date: September 26, 2017
• Est. completion date: August 25, 2021

Study information

• Verified date: January 2024
• Source: Augusta University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase 1b/2 study to determine the safety and effectiveness of the combination of pembrolizumab and idelalisib in NSCLC patients whose disease has stopped responding to immune therapy. This study is being done to see if adding another immune modulator (idelalisib) to standard pembrolizumab will increase response rates, compared to the response seen with pembrolizumab alone.

Description:

This is a phase 1b/2 study to determine the safety and effectiveness of the combination of pembrolizumab and idelalisib in NSCLC patients whose disease has stopped responding to immune therapy. Pembrolizumab is an anti-PD-1 immunotherapy that is given intravenously and is approved for treatment of malignant NSCLC. Idelalisib is the first-in-class oral PI3K-δ inhibitor that is approved for treatment of certain forms of leukemia and lymphoma.

Immune checkpoint inhibitors (such as anti-PD-1) are effective in treating NSCLC as a single agent, but overall response isn't optimal; overall response rates (ORR) are only ~20% on average. The goal of this study is to see whether combining standard therapy with additional immune modulators will increase response rates, compared to the response seen with pembrolizumab monotherapy.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 4
• Est. completion date: August 25, 2021
• Est. primary completion date: August 15, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

All subjects must have documented metastatic or recurrent NSCLC from biopsy. They must have failed or progressed on platinum-based chemotherapy (e.g. cisplatin, carboplatin) as well as immune checkpoint inhibitor therapy (e.g nivolumab or pembrolizumab). Patients with EGFR/ALK mutations/translocations must have failed or progressed on small molecule inhibitor therapies (e.g. erlotinib, afatinib, etc.).

Inclusion Criteria:

• Have at least one measurable lesion

• Have an ECOG Performance Status of 1 or less

• Demonstrate adequate organ function as defined in the protocol.

• Female subjects of childbearing potential must have a negative pregnancy test before starting treatment; they must also be willing to use two methods of birth control or abstain from heterosexual activity for the duration of the study.

• Male subjects must agree to use an adequate method of contraception starting with the first dose of study therapy through the duration of the study.

Exclusion Criteria:

• Is currently receiving study drug in another trial; or has participated in an investigational drug study within 3 weeks of the first dose of treatment.

• Is within 3 weeks of most recent chemotherapy.

• Has a history of hypersensitivity to pembrolizumab or idelalisib, or any of their excipients.

• Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated, stable, brain metastases may participate; carcinomatous meningitis is excluded regardless of clinical stability.

• Has known history of non-infectious pneumonitis that required steroid use or has current pneumonitis.

• Has a known history of active TB (Bacillus Tuberculosis)

• Has active autoimmune disease that has required treatment; known history of Human Immunodeficiency Virus (HIV); known active Hepatitis B or Hepatitis C.

• Has an active infection requiring systemic therapy.

• Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Metastasis
• Neoplasm Metastasis
• Non Small Cell Lung Cancer
• Recurrence

Intervention

Drug:
• Pembrolizumab
Anti PD-1 immunotherapeutic agent, which blocks a protective mechanism on cancer cells to allow the immune system to destroy cancer cells. Administered intravenously (IV).
• Idelalisib
Phosphatidylinositol 3-kinase (PI3K) inhibitor which promotes anti-tumor immune response. Administered orally (PO).

Locations

Country	Name	City	State
United States	Georgia Cancer Center at Augusta University	Augusta	Georgia

Sponsors (3)

Lead Sponsor	Collaborator
Asha Nayak	Gilead Sciences, Merck Sharp & Dohme LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Dose-Limiting Toxicity (DLT) Events as Assessed by CTCAE v4.03	Modified 3+3 dose escalation design will be used to determine whether the addition of idelalisib to standard pembrolizumab is safe and tolerable in checkpoint inhibitor refractory NSCLC patients. An initial cohort of 3 patients will receive 50 mg twice daily idelalisib with standard pembrolizumab. If none of the 3 patients develop a DLT, another 3 patients will be enrolled. Dose will be escalated or de-escalated based on the occurrence of DLTs. All events will be assessed for possible, probable, or definite relation to idelalisib.	First 9 weeks at each dose level
Secondary	Dose-Finding Assessment for Optimum Dose of Idelalisib in Combination With Pembrolizumab	Determine the phase 2 recommended dose (P2RD) of idelalisib, in combination with pembrolizumab, in patients with checkpoint inhibitor refractory NSCLC. If no more than 1/6 patients in initial cohort develop a DLT, the patients will be tested for T-regulatory cell function suppression (80% suppression in 80% of patients). If dose is escalated or de-escalated, testing will continue to assess for optimal T-reg suppression. The dose at which the tolerability and suppression criteria are both met will be declared the P2RD and the study will proceed to phase 2.	18-27 weeks
Secondary	Overall Response Rates (ORR) to Combination Therapy	Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.	18 weeks - 2 years